Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Which Offers More Control: Index Fund Or Target Date Retirement. Understand where you have more say over allocations and timing for retirement planning.
28,368 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Fermi America slumped 11.5% as it unveiled a $375 million convertible note offering and reported a Q1 with zero reven...
A major EV maker partners with Uber on a robotaxi plan, sending ripples through the market. This guide breaks down wh...
Thinking long term pays off in the stock market. This guide reveals three growth stock archetypes you can buy and hol...
As Zepp Health nears the release of its Q1 2026 earnings, investors want clarity on growth, margins, and strategic be...
Lawmakers and insurers are weighing a faster disaster payout model that would centralize leadership and pool risk to ...
When a top executive sells a large block of stock, investors want to know whether it signals trouble or simply person...
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
When high-growth stocks stumble after earnings, it sparks questions for investors. This article digs into why On Hold...
A major family-office investor has increased its position in Middleby as the company prepares a spin-off. This move o...
Could buying sweetgreen stock be a gateway to lasting wealth, or is it a risky turnaround bet? This guide cuts throug...
Bitcoin cleared the $70,000 barrier and moved toward $74,000, sparking bets on higher bitcoin’s next price targets as...